Niacin and laropiprant

Drugs of Today

Volumn 46, Issue 6, 2010, Pages 371-378

  Sanyal, S ^a   Kuvin, J T ^a   Karas, Richard H ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; MIDAZOLAM; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SIMVASTATIN; IMMUNOGLOBULIN RECEPTOR; INDOLE DERIVATIVE; MK-0524; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

AEROBIC EXERCISE; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; HUMAN; HYPERLIPIDEMIA; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; SMOKING CESSATION; THROMBOCYTE FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG TOLERANCE; EXERCISE; METABOLISM; SAFETY;

CHOLESTEROL, HDL; DRUG TOLERANCE; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPOPROTEINS, HDL; NIACIN; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SAFETY; WEIGHT LOSS;

EID: 77955439526     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.6.1464844     Document Type: Review

References (45)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19): 2486-97.
2. Toth, P.P. High-density lipoprotein as a therapeutic target: Clinical evidence and treatment strategies. Am J Cardiol 2005, 96(9A): 50K-58K, discussion 34K-35K.
3. Assmann, G., Schulte, H., von Eckardstein, A., Huang, Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl.): S11-20.
4. Barter, P., Gotto, A.M., LaRosa, J.C. et al.; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357(13): 1301-10.
5. Barter, P.J., Rye, K.A. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 1996, 7(2): 82-7.
6. Negre-Salvayre, A., Dousset, N., Ferretti, G., Bacchetti, T., Curatola, G., Salvayre, R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006, 41(7): 1031-40.
7. Kuvin, J.T., Patel, A.R., Sliney, K.A. et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003, 146(1): 168-74.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106(25): 3143-421.
9. Clofibrate and niacin in coronary heart disease. JAMA 1975, 231(4): 360-81.
10. Canner, P.L., Berge, K.G., Wenger, N.K. Stamler, J., Friedman, L., Prineas, R.J., Friedewald, W. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986, 8(6): 1245-55.
11. Brown, B.G., Zhao, X.Q., Chait, A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345(22): 1583-92.
12. Taylor, A.J., Sullenberger, L.E., Lee, H.J., Lee, J.K., Grace, K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110(23): 3512-7.
13. Taylor, A.J., Villines, T.C., Stanek, E.J. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22): 2113-22.
14. Kuvin, J.T., Dave, D.M., Sliney, K.A. et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006, 98(6): 743-5.
15. Kamal-Bahl, S., Watson, D.J., Ambegaonkar, B.M. Patients' experiences of niacin-induced flushing in clinical practice: A structured telephone interview. Clin Ther 2009, 31(1): 130-40.
16. Rubenfire, M. Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the impact of medical subspecialty on patient compliance to treatment (IMPACT) study. Am J Cardiol 2004, 94(3): 306-11.
17. Morrow, J.D., Parsons, W.G. 3rd, Roberts, L.J. 2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38(2): 263-74.
18. Andersson, R.G., Aberg, G., Brattsand, R., Ericsson, E., Lundholm, L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh) 1977, 41(1): 1-10.
19. Eklund, B., Kaijser, L., Nowak, J., Wennmalm, A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 1979, 17(6): 821-30.
20. Kaijser, L., Eklund, B., Olsson, A.G., Carlson, L.A. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979, 57(2): 114-7.
21. Olsson, A.G., Carlson, L.A., Anggard, E., Ciabattoni, G. Prostacyclin production augmented in the short term by nicotinic acid. Lancet 1983, 2(8349): 565-6.
22. Tunaru, S., Kero, J., Schaub, A.,Wufka, C., Blaukat, A., Pfeffer, K., Offermanns, S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9(3): 352-5.
23. Benyo, Z., Gille, A., Kero, J. et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005, 115(12): 3634-40.
24. Morrow, J.D., Awad, J.A., Oates, J.A., Roberts, L.J. 2nd. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992, 98(5): 812-5.
25. Benyo, Z., Gille, A., Bennett, C.L., Clausen, B.E., Offermanns, S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006, 70(6): 1844-9.
26. Hirai, H., Tanaka, K., Yoshie, O. et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001, 193(2): 255-61.
27. Hirata, M., Kakizuka, A., Aizawa, M., Ushikubi, F., Narumiya, S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci U S A 1994, 91(23): 11192-6.
28. Monneret, G., Gravel, S., Diamond, M., Rokach, J., Powell, W.S. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001, 98(6): 1942-8.
29. Cheng, K., Wu, T.J., Wu, K.K. et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006, 103(17): 6682-7.
30. Dunn, R.T., Ford, M.A., Rindone, J.P., Kwiecinski, F.A. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995, 2(7): 478-80.
31. Guyton, J.R., Bays, H.E. Safety considerations with niacin therapy. Am J Cardiol 2007, 99(6A): 22C-31C.
32. Karanam, B., Madeira, M., Bradley, S. et al. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Drug Metab Dispos 2007, 35(7): 1196-202.
33. Tredaptive European prescribing information. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tredaptive/emea-combined-h889eu. pdf.
34. Stroh, M., Wenning, L., Luo, W.L. et al. Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. Am J Ther 2009, 16(5): 379-84.
35. Lai, E., Wenning, L.A., Crumley, T.M. et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008, 83(6): 840-7.
36. Maccubbin, D., Koren, M.J., Davidson, M. et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009, 104(1): 74-81.
37. Paolini, J.F., Bays, H.E., Ballantyne, C.M. et at. Extended-release niacin/laropiprant: Reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008, 26(4): 547-60.
38. Kush, D., Kim, H.S., Hu, D.Y. et at. Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia. Journal of Clinical Lipidology 2009, 3(3): 179-86.
39. Kush, D., Hu, D.Y., Ye, P. et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in asian lipid clinic patients. Cardiology 2009, 114(3): 192-8.
40. Maccubbin, D., Bays, H.E., Olsson, A.G. et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidaemia. Int J Clin Pract 2008, 62(12): 1959-70.
41. Dishy, V., Liu, F., Ebel, D.L. et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009, 49(4): 416-22.
42. Gleim, G., Liu, N., Thompson-Bell, S. et al. Efficacy and safety profile of coadministered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009, 16(2): 90-7.
43. Martinez, L.O., Jacquet, S., Esteve, J.P. et al. Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421(6918): 75-9.
44. Zhang, L.H., Meyers, C.D., Kamanna, V.S., Kashyap, M.L. Niacin inhibits β chain ATP synthase cell surface expression in HepG2 cells. Mechanistic implications for raising HDL.Aterioscler Thromb Vasc Biol 2006, 26: E-53.
45. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE (NCT00461630). ClinicalTrials.gov Web Site, May 15, 2010.